SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ANI Pharmaceuticals, Inc. (ANIP) trades at a trailing P/E of 21.0, forward P/E of 8.7. Trailing earnings yield is 4.77%, forward earnings yield 11.56%. PEG 0.05 (Peter Lynch undervalued ≤1.0). Graham Number is $47.91.
Criteria proven by this page:
- VALUE (86/100, Pass) — P/E is below market average (21.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.05); analyst target implies upside (+36.7%); earnings yield beats bond yields (4.77%).
- Forward P/E 8.7 (down from trailing 21.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.05 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.77% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 11.56% as earnings recover.
- Analyst consensus target $107.00 (+36.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 70/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
86/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ANIP
Valuation Multiples
P/E (TTM)21.0
Forward P/E8.7
PEG Ratio0.05
Forward PEG0.05
P/B Ratio2.94
P/S Ratio2.02
EV/EBITDA8.1
Per Share Data
EPS (TTM)$3.78
Forward EPS (Est.)$9.05
Book Value / Share$26.96
Revenue / Share$44.05
FCF / Share$6.41
Yields & Fair Value
Earnings Yield4.77%
Forward Earnings Yield11.56%
Dividend Yield0.00%
Graham Number$47.91
SharesGrow IV$482.01 (+515.7%)
Analyst Target$107.00 (+36.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
176.4 |
-2.36 |
4.09 |
5.39 |
- |
| 2017 |
-691.6 |
5.43 |
4.26 |
4.21 |
- |
| 2018 |
33.9 |
-0.02 |
2.66 |
2.61 |
- |
| 2019 |
119.8 |
-1.94 |
3.43 |
3.54 |
- |
| 2020 |
-15.4 |
0.03 |
1.78 |
1.67 |
- |
| 2021 |
-13.6 |
-0.17 |
1.62 |
2.69 |
0.03% |
| 2022 |
-13.7 |
1.33 |
1.93 |
2.07 |
0.25% |
| 2023 |
52.9 |
-0.40 |
2.17 |
2.04 |
0.16% |
| 2024 |
-57.7 |
0.28 |
2.49 |
1.74 |
0.15% |
| 2025 |
20.2 |
-0.05 |
2.93 |
1.79 |
0.07% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.34 |
$128.62M |
$3.93M |
3.1% |
| 2017 |
$-0.09 |
$176.84M |
$-1.08M |
-0.6% |
| 2018 |
$1.32 |
$201.58M |
$15.49M |
7.7% |
| 2019 |
$0.50 |
$206.55M |
$6.09M |
3% |
| 2020 |
$-1.88 |
$208.48M |
$-22.55M |
-10.8% |
| 2021 |
$-3.38 |
$216.14M |
$-42.6M |
-19.7% |
| 2022 |
$-2.95 |
$316.39M |
$-47.9M |
-15.1% |
| 2023 |
$0.94 |
$486.82M |
$18.78M |
3.9% |
| 2024 |
$-0.87 |
$614.38M |
$-18.52M |
-3% |
| 2025 |
$3.32 |
$883.37M |
$78.34M |
8.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$9.05 |
$8.87 – $9.17 |
$1.09B |
$1.07B – $1.11B |
5 |
| 2027 |
$10.57 |
$9.71 – $11.67 |
$1.21B |
$1.14B – $1.26B |
4 |
| 2028 |
$12.46 |
$11.78 – $12.92 |
$1.3B |
$1.29B – $1.31B |
3 |
| 2029 |
$12.69 |
$11.99 – $13.16 |
$1.37B |
$1.32B – $1.41B |
2 |
| 2030 |
$13.45 |
$12.71 – $13.95 |
$1.5B |
$1.43B – $1.54B |
2 |
